Cookies

Like most websites The Pathologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Diagnostics Neurology, Quality assurance and quality control, Analytical science

Avoid Mass Spec-ulation: Use References

Analysis of beta-amyloid in the cerebrospinal fluid (CSF) is an increasingly common method for early diagnosis of Alzheimer’s disease (AD), and is seeing use in both clinical and research settings. But just how accurate are these tests? A reference method for harmonizing beta-amyloid measurement, developed by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Scientific Division Working Group on CSF proteins, has now been formally classified as the international standard, in order to address current issues with diagnostic testing.

Although several assays exist for measuring beta-amyloid in CSF, problems like matrix effects, different testing platforms, and a lack of defined standards, means these tests may not be directly comparable – affecting general cutoff measurements, and hampering interlaboratory comparisons of tests. The IFCC working group set out to solve the problem by developing a validated reference measurement procedure to reduce the variability in AD biomarker results.

“The primary use of this test will not be in general laboratories. It will be used in specialized laboratories to measure the absolute concentration of beta-amyloid 1-42 in certified reference materials that will be used by commercial kit producers to calibrate their assays,” says Henrik Zetterberg, a member of the working group, and co-author of the associated paper (1). “The main benefit is that the method is not dependent on antibodies – it is a mass spec-based assay in which the CSF sample is denatured, liberating all beta-amyloid 1-42 and making it accessible to measurement. The denaturing step prior to analysis makes us certain that no beta-amyloid 1-42 escapes our detection,” he adds.

The reference materials based on the method will be made available to the producers of AD testing kits at a not-for-profit cost, via the Institute of Reference Materials and Measurements in Belgium.

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. A Leinenbach, et al., “Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-β in cerebrospinal fluid”, Clin  Chem, 60, 987–994 (2014). PMID: 24842955.
About the Author
Roisin McGuigan

I have an extensive academic background in the life sciences, having studied forensic biology and human medical genetics in my time at Strathclyde and Glasgow Universities. My research, data presentation and bioinformatics skills plus my ‘wet lab’ experience have been a superb grounding for my role as an Associate Editor at Texere Publishing. The job allows me to utilize my hard-learned academic skills and experience in my current position within an exciting and contemporary publishing company.

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register